drugset
drugset / Trial / NCT02576548

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

NCT02576548 ↗

Phase 1 Completed 47 enrolled MedImmune LLC
NaSingle-groupOpen-labelTreatment

Summary

This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.

Timeline

Start
2015-09-23
Primary completion
2018-05-23
Completion
2018-05-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI4276 Unknown 0.05 mg/kg Intravenous
Subject MEDI4276 Unknown 0.1 mg/kg Intravenous
Subject MEDI4276 Unknown 0.2 mg/kg Intravenous
Subject MEDI4276 Unknown 0.3 mg/kg Intravenous
Subject MEDI4276 Unknown 0.4 mg/kg Intravenous
Subject MEDI4276 Unknown 0.5 mg/kg Intravenous
Subject MEDI4276 Unknown 0.6 mg/kg Intravenous
Subject MEDI4276 Unknown 0.75 mg/kg Intravenous
Subject MEDI4276 Unknown 0.9 mg/kg Intravenous

Indications

carcinoma